Adenovirus serotype 5 vaccine vector |
|
Vaxvec ID |
38 |
|
Vaccine Vector Name |
Adenovirus serotype 5 vaccine vector |
|
Alternative Names |
Ad5 |
|
Vector VO ID |
VO_0001081
|
|
Advantage |
The adenovirus serotype 5 vaccine vector has demonstrated a certain capability to generate protective immune response against disease (Lu et al., 2012). |
|
Disadvantage |
A large amount of pre-existing immunity to Ad5 creates a great disadvantage for this vector. Preclinical trials concerning rodents and nonhuman primates indicated that this immunity is capable of diminishing or even eradicating the vaccine's immunogenicity. Some studies have implied that the existence of antibodies against Ad5 vectors may augment toxicities associated with this vector (Lu et al., 2012). |
|
Description |
The adenovirus serotype 5 vaccine vector is an adenoviral vector. Its genome size is approximately 35934 bp. This vector largely depends on interaction with the coxsackievirus-adenovirus receptors to mediate gene delivery, allowing for adenovirus vector to be unqualified for a large variety of diseases (Lu et al., 2012). |
| Related Vaccine(s) |
|
| References |
Lu et al., 2012: Lu HY, Chen YH, Liu HJ. Baculovirus as a vaccine vector. Bioengineered. 2012; 3(5); 271-274. [PubMed: 22705893].
|
